Search - tctmd.com

Displaying 101 - 120 of 700

Sort: Relevancy | Date

News Conference News ACC 2018

NOTION: 5-Year Outcomes for TAVR Match SAVR in Low-Risk Patients

Shelley Wood

March 10, 2018

News Conference News CRT 2018

Transcatheter Fix for Native Aortic Valve Regurgitation ‘Not Optimal’ but Getting Better

Shelley Wood

March 05, 2018

News Daily News

Preexisting Prosthesis-Patient Mismatch Signals Worse Aortic Valve-in-Valve Outcomes

Todd Neale

January 17, 2018

News Daily News

REPRISE III in Print: Now With Comparison Between Lotus, Evolut R

Shelley Wood

January 05, 2018

News Daily News

New-Generation TAVR Devices Outperform Predecessors in Treating Pure Native AR: Registry

Caitlin E. Cox

November 30, 2017

News Conference News TCT 2017

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Yael L. Maxwell

November 09, 2017

News Conference News TCT 2017

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Michael O'Riordan

October 31, 2017

Manuscript

Cost-Effectiveness and Projected Survival of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement for High Risk Patients in a European Setting: A Dutch Analysis Based on the CoreValve High Risk Trial

October 05, 2017

News Daily News

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Michael O'Riordan

September 27, 2017

News Conference News PCR London Valves 2017

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

Shelley Wood

September 27, 2017

News Conference News ESC 2017

Nonagenarians Fare Well After TAVR, Once They Get Beyond 30 Days

Michael O'Riordan

August 31, 2017

News Conference News ESC 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Shelley Wood

August 27, 2017

News Industry News

Medtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with Advanced Sealing

August 01, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2017

Shelley Wood

July 31, 2017

News Daily News

TAVR Equivalent to Surgery in Real-World Practice, New Analysis Shows

Michael O'Riordan

July 17, 2017

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Daily News

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Michael O'Riordan

June 26, 2017

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Shelley Wood

June 19, 2017

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

Advertisement

NOTION: 5-Year Outcomes for TAVR Match SAVR in Low-Risk Patients

Transcatheter Fix for Native Aortic Valve Regurgitation ‘Not Optimal’ but Getting Better

Preexisting Prosthesis-Patient Mismatch Signals Worse Aortic Valve-in-Valve Outcomes

REPRISE III in Print: Now With Comparison Between Lotus, Evolut R

New-Generation TAVR Devices Outperform Predecessors in Treating Pure Native AR: Registry

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Cost-Effectiveness and Projected Survival of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement for High Risk Patients in a European Setting: A Dutch Analysis Based on the CoreValve High Risk Trial

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

Nonagenarians Fare Well After TAVR, Once They Get Beyond 30 Days

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Medtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with Advanced Sealing

TCTMD’s Top 10 Most Popular Stories for July 2017

TAVR Equivalent to Surgery in Real-World Practice, New Analysis Shows

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content